BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Timpani CA, Rybalka E. Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19. Pharmaceuticals (Basel) 2020;14:15. [PMID: 33375288 DOI: 10.3390/ph14010015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Thomas SD, Jha NK, Sadek B, Ojha S. Repurposing Dimethyl Fumarate for Cardiovascular Diseases: Pharmacological Effects, Molecular Mechanisms, and Therapeutic Promise. Pharmaceuticals 2022;15:497. [DOI: 10.3390/ph15050497] [Reference Citation Analysis]
2 Piñar Morales R, Ramírez Rivas MA, Barrero Hernández FJ. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis. Neurologia (Engl Ed) 2021:S2173-5808(21)00079-1. [PMID: 34103271 DOI: 10.1016/j.nrleng.2021.03.002] [Reference Citation Analysis]
3 Naghavi S, Kavosh A, Adibi I, Shaygannejad V, Arabi S, Rahimi M, Mazaheri S, Ashtari F. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021. Mult Scler Relat Disord 2022;57:103335. [PMID: 35158427 DOI: 10.1016/j.msard.2021.103335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ambrosino P, Calcaterra IL, Mosella M, Formisano R, D’anna SE, Bachetti T, Marcuccio G, Galloway B, Mancini FP, Papa A, Motta A, Di Minno MND, Maniscalco M. Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target. Biomedicines 2022;10:812. [DOI: 10.3390/biomedicines10040812] [Reference Citation Analysis]
5 Sánchez-García FJ, Pérez-Hernández CA, Rodríguez-Murillo M, Moreno-Altamirano MMB. The Role of Tricarboxylic Acid Cycle Metabolites in Viral Infections. Front Cell Infect Microbiol 2021;11:725043. [PMID: 34595133 DOI: 10.3389/fcimb.2021.725043] [Reference Citation Analysis]
6 Stoy N. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front Immunol 2021;12:638446. [PMID: 33936053 DOI: 10.3389/fimmu.2021.638446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Esposito M, Campanati A, Giunta A, Calianno G, Bianchi L, Diotallevi F, Offidani AM, Fargnoli MC. Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic. Dermatol Ther (Heidelb) 2022. [PMID: 35103934 DOI: 10.1007/s13555-022-00684-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Alam MS, Czajkowsky DM. SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine Growth Factor Rev 2021:S1359-6101(21)00080-0. [PMID: 34836751 DOI: 10.1016/j.cytogfr.2021.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Emanuele S, Celesia A, D'Anneo A, Lauricella M, Carlisi D, De Blasio A, Giuliano M. The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19. Int J Mol Sci 2021;22:7963. [PMID: 34360732 DOI: 10.3390/ijms22157963] [Reference Citation Analysis]
10 Long MJC, Aye Y. Science's Response to CoVID-19. ChemMedChem 2021;16:2288-314. [PMID: 33811458 DOI: 10.1002/cmdc.202100079] [Reference Citation Analysis]
11 Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Orphanet J Rare Dis 2021;16:117. [PMID: 33663533 DOI: 10.1186/s13023-021-01758-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]